Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia

Cheng Wang, Jianfeng Li, Weiyang Liu, Yuchen Yan, Li-Jun Peng, Jiayi Ren, Yongmei Zhu, Xiangqin Weng, Jiong Hu, Yuanfang Liu, Jie Hao, Weiping Zhang, Duohui Jing, Jian-Qing Mi, JIN WANG

Blood (2025) 146 (Supplement 1): 6880.

https://doi.org/10.1182/blood-2025-6880

Published: 2025

Journal Articles

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Yuchen Yan, Ligen Liu, Jie Hao, Xiaofeng Han, Ping Li, Libing Wang, Li Yang, Yong Tang, Cheng Wang, Weiyang Liu, Jiayi Ren, Jiong Hu, Jianmin Yang, Qi Zhu, Aibin Liang, Jian Hou, Xianmin Song, Jianqing Mi, JIN WANG

Blood (2025) 146 (Supplement 1): 6830.

https://doi.org/10.1182/blood-2025-6830

Published: 2025

Journal Articles

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment

Junyu Wang, Bo Jiao, Tuantuan Gui, Xuan Liu, Shan-Shan Guo, Cheng Wang, Weiyang Liu, Li-Jun Peng, Jiayi Ren, Ming Zhang, Yun Tan, Duohui Jing, Jian-Qing Mi, Tong Yin, Hai Fang, Sai-Juan Chen, JIN WANG

Blood (2025) 146 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2025-3362

Published: 2025

Journal Articles

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol

Jiayi Ren, Li-Jun Peng, Weiyang Liu, Jiong Hu, Cheng Wang, Yuchen Yan, Yuanfang LIU, Weiping Zhang, JIN WANG, Jian-Qing Mi

Blood (2025) 146 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2025-3333

Published: 2025

Journal Articles

Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1 plus genotyping and MRD Assessment in Adult BCR::ABL1 -Positive Acute Lymphoblastic Leukemia

Cheng Wang, Jianfeng Li, Weiyang Liu, Han Yan, Yuchen Yan, Lingling Zhao, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Xiangqin Weng, Yongmei Zhu, Weiping Zhang, Jie Xu, Duohui Jing, Jian-Qing Mi, Jin Wang

Blood (2024) 144 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2024-209664

Published: 2024

Journal Articles

Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease

Lijun Peng, Yuting Dai, Jiayi Ren, Weiyang Liu, Jie Xu, Weiping Zhang, Jin Wang, Jian-Qing Mi

Blood (2024) 144 (Supplement 1): 4210.

https://doi.org/10.1182/blood-2024-204740

Published: 2024

Journal Articles

A Hiplot-Based Web Application for the Rapid Prediction of Adult BCR::ABL1 -Positive and BCR::ABL1 -like B-Cell Precursor Acute Lymphoblastic Leukemia

Jianfeng Li, Yuchen Yan, Cheng Wang, Weiyang Liu, Han Yan, Lingling Zhao, Xiangqin Weng, Yongmei Zhu, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Weiping Zhang, Jie Xu, Duohui Jing, Jian-Qing Mi, Jin Wang

Blood (2024) 144 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2024-210369

Published: 2024

Journal Articles

Flumatinib with Low-Intensity Chemotherapy in Elderly Patients with Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia

Weiyang Liu, Yuanfang Liu, Yongmei Zhu, Xiangqin Weng, Cheng Wang, Wanyan Ouyang, Jie Xu, Weiping Zhang, Jin Wang, Jian-Qing Mi

Blood (2024) 144 (Supplement 1): 5883.

https://doi.org/10.1182/blood-2024-210222

Published: 2024

Journal Articles

The Prognostic Significance of 1-Year Persistent MRD Negativity in Chinese ALL Patients: 5-Year Follow-up Results from RJ-ALL 2014 Trial

Jiayi Ren, Sijie Tang, Weiyang Liu, Xiangqin Weng, Cheng Wang, Lijun Peng, Wenqian Xu, Yuxuan Shang, Jie Hao, Wenyan Yu, Jiaojiao Zhang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jin Wang, Jian-Qing Mi

Blood (2023) 142 (Supplement 1): 6057.

https://doi.org/10.1182/blood-2023-189710

Published: 2023

Journal Articles

Dose Escalation of Blinatumomab Is a Better Option for MRD-Positive CR Patients, Results from a Single-Center Real World Study of Blinatumomab for B-Cell Acute Lymphoblastic Leukemia in China

Sijie Tang, Jiayi Ren, Weiyang Liu, Xiangqin Weng, Yongmei Zhu, Cheng Wang, Lijun Peng, Wenqian Xu, Yuxuan Shang, Wenyan Yu, Jiaojiao Zhang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jian-Qing Mi, Jin Wang

Blood (2023) 142 (Supplement 1): 5885.

https://doi.org/10.1182/blood-2023-189703

Published: 2023

Journal Articles

A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia in Adults: Updated Results from RJ-ALL2020.2A Trial

Weiyang Liu, Cheng Wang, Sijie Tang, Jiayi Ren, Lijun Peng, Yongmei Zhu, Xiangqin Weng, Wanyan Ouyang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jian-Qing Mi, Jin Wang

Blood (2023) 142 (Supplement 1): 5880.

https://doi.org/10.1182/blood-2023-180326

Published: 2023

Journal Articles

The Promising Third-Generation TKI Olverembatinib in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed/Refractory Disease

Weiyang Liu, Cheng Wang, Sijie Tang, Jiayi Ren, Lijun Peng, Yongmei Zhu, Xiangqin Weng, Wanyan Ouyang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jin Wang, Jian-Qing Mi

Blood (2023) 142 (Supplement 1): 5902.

https://doi.org/10.1182/blood-2023-188733

Published: 2023

Journal Articles

The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease

Weiyang Liu, Yuanfang Liu, Yongmei Zhu, Xiangqin Weng, Cheng Wang, Wanyan Ouyang, Jie Xu, Jin Wang, Jian-Qing Mi

Blood (2022) 140 (Supplement 1): 3266–3267.

https://doi.org/10.1182/blood-2022-166482

Published: 2022

Journal Articles

A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial

Weiyang Liu, Yuanfang Liu, Yongmei Zhu, Xiangqin Weng, Cheng Wang, Wanyan Ouyang, Jie Xu, Jian-Qing Mi, Jin Wang

Blood (2022) 140 (Supplement 1): 8981–8982.

https://doi.org/10.1182/blood-2022-165259

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol

Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1 plus genotyping and MRD Assessment in Adult BCR::ABL1 -Positive Acute Lymphoblastic Leukemia

Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease

A Hiplot-Based Web Application for the Rapid Prediction of Adult BCR::ABL1 -Positive and BCR::ABL1 -like B-Cell Precursor Acute Lymphoblastic Leukemia

Flumatinib with Low-Intensity Chemotherapy in Elderly Patients with Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia

The Prognostic Significance of 1-Year Persistent MRD Negativity in Chinese ALL Patients: 5-Year Follow-up Results from RJ-ALL 2014 Trial

Dose Escalation of Blinatumomab Is a Better Option for MRD-Positive CR Patients, Results from a Single-Center Real World Study of Blinatumomab for B-Cell Acute Lymphoblastic Leukemia in China

A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia in Adults: Updated Results from RJ-ALL2020.2A Trial

The Promising Third-Generation TKI Olverembatinib in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed/Refractory Disease

The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease

A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only